- Home
- ODD vs PRLD Comparison
ODD vs PRLD Comparison
Compare ODD & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | PRLD |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 973.7M | 260.2M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ODD | PRLD |
|---|---|---|
| Price | $23.36 | $3.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $15.56 | $9.20 |
| AVG Volume (30 Days) | ★ 677.8K | 444.7K |
| Earning Date | 11-18-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $258.83 |
| Revenue Next Year | $14.12 | N/A |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $9.25 | $1.17 |
| 52 Week High | $47.78 | $6.83 |
Technical Indicators
Market Signals| Indicator | ODD | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 40.14 |
| Support Level | $11.96 | $3.48 |
| Resistance Level | $32.72 | $4.07 |
| Average True Range (ATR) | 1.27 | 0.25 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 89.88 | 45.31 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.